Blood urea nitrogen has additive value beyond estimated glomerular filtration rate for prediction of long-term mortality in patients with acute myocardial infarction.


Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
01 2019
Historique:
received: 21 03 2018
revised: 28 06 2018
accepted: 22 07 2018
pubmed: 4 8 2018
medline: 22 5 2019
entrez: 4 8 2018
Statut: ppublish

Résumé

Blood urea nitrogen (BUN) has been shown to independently predict short- and intermediate-term outcomes in patients with acute myocardial infarction (AMI). We aimed to assess the additive predictive value of BUN beyond estimated glomerular filtration rate (eGFR) in AMI patients with an 8.6-year follow-up. This retrospective, observational single-centre study included 1332 consecutive AMI patients (median age 64 years, 58.4% male). BUN, creatinine and eGFR were determined at hospital admission. During a median follow-up of 8.6 years (interquartile range [IQR] 4.0-11.6), 408 patients (30.6%) experienced the study endpoint of cardiovascular mortality. BUN (median 17.0 mg/dL [IQR 13.5-22.7]) was a significant predictor of cardiovascular mortality in univariate Cox regression (hazard ratio (HR) per 1 standard deviation increase 2.10, 95% confidence interval [CI] 1.94-2.28, p < .001). This association remained significant after multivariable adjustment for demographics, clinical variables and eGFR (adjusted HR 1.52 [CI 1.16-2.00, p = .003]). The association between BUN and outcome was more pronounced in patients with eGFR >60 mL/min/1.73m Circulating BUN on admission is an independent predictor of long-term cardiovascular mortality in AMI patients and adds predictive power beyond eGFR. BUN reflects not only kidney function, but also acute haemodynamic and neurohumoral alterations during AMI, and may help to identify high-risk patients.

Identifiants

pubmed: 30072202
pii: S0953-6205(18)30291-7
doi: 10.1016/j.ejim.2018.07.019
pii:
doi:

Substances chimiques

Biomarkers 0
Creatinine AYI8EX34EU

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

84-90

Informations de copyright

Copyright © 2018 European Federation of Internal Medicine. All rights reserved.

Auteurs

Bernhard Richter (B)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Patrick Sulzgruber (P)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Lorenz Koller (L)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Matthias Steininger (M)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Feras El-Hamid (F)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

David J Rothgerber (DJ)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Stefan Forster (S)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Georg Goliasch (G)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Benjamin I Silbert (BI)

Department of Intensive Care Medicine, Fiona Stanley Hospital, Murdoch, Australia.

Elias L Meyer (EL)

Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Austria.

Christian Hengstenberg (C)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Johann Wojta (J)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria.

Alexander Niessner (A)

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Austria. Electronic address: alexander.niessner@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH